SCHEDULE: Vanguard Discloses 4.83% Stake in Monte Rosa Therapeutics

The Vanguard Group reported a 4.83% beneficial ownership stake in Monte Rosa Therapeutics Inc. common stock as of September 30, 2025.

Summary

• The Vanguard Group, an investment adviser, has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Monte Rosa Therapeutics Inc.
• As of September 30, 2025, The Vanguard Group beneficially owned 2,988,953 shares of Monte Rosa Therapeutics Inc. Common Stock.
• This ownership represents 4.83% of the class of securities.
• The Vanguard Group holds sole dispositive power over 2,682,089 shares and shared dispositive power over 306,864 shares.
• The Vanguard Group holds shared voting power over 288,726 shares and no sole voting power.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a significant institutional ownership stake by The Vanguard Group, indicating continued institutional interest in Monte Rosa Therapeutics Inc. This is generally a neutral to slightly positive signal.

Positives

• The disclosure of a significant stake by a major institutional investor like The Vanguard Group indicates continued institutional interest in Monte Rosa Therapeutics Inc.
• The holding of 2,988,953 shares by Vanguard suggests a degree of confidence from a large, reputable asset manager.

Negatives

• No specific negative information regarding Monte Rosa Therapeutics Inc. is contained within this beneficial ownership disclosure.

Risks

• NA

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders benefit from increased transparency regarding significant institutional holdings, which can influence market perception and liquidity.
• The presence of a large institutional investor like Vanguard may provide a degree of stability to the shareholder base.

Key Dates

Keywords

Vanguard Group, Monte Rosa Therapeutics, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Investment Adviser, Equity Stake